HALIFAX, April 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, and US-based sales and marketing partner American Health Diagnostics LLC (AHD), announced today that their South East Asia market expansion initiatives have resulted in product sales in Indonesia. As announced in August 2008, MedMira and AHD are working together to break in to this developing market and sell at least one million rapid HIV tests in the South East Asia region over the next year.
Local distributors Lauw Management USA and PT Sehat Selaras Sejahtera, along with MedMira and AHD pursued and received regulatory approval in Indonesia for MedMira's MiraWell Rapid HIV Test (MiraWell HIV). In addition to regulatory approval, the sales and marketing registrations required to sell the product in this market has also been completed.
"We have converted our Southeast Asia market expansion into concrete sales opportunities in Indonesia. Working with our partners, AHD, Lauw Management USA, and PT Sehat Selaras Sejahtera, we were able to move through the evaluation and regulatory process smoothly in order to realize our first sales in the region," said Hermes Chan, president and CEO, MedMira Inc. "This is the first in a series of initiatives included in our market development plan for the region. Working with our strategic partners in South East Asia we will sell our competitively priced, quality diagnostics to other countries in the region."
AHD, Lauw Management USA, and PT Sehat Selaras Sejahtera will use the first shipment of MiraWell HIV to target both private and public sector customers. With a comprehensive sales and marketing campaign slated to begin in May, follow-on orders are anticipated in the coming months.
"We are very excited about bringing this product to customers in Indonesia," said Brad Adams, Executive Vice President of AHD. "We are well on our way to establishing MiraWell HIV as a brand known for quality and performance and fully developing the sales opportunities that exist in Indonesia for this product."
About American Health Diagnostics
American Health Diagnostics brings innovations to life through a proprietary market readiness process and proven distribution management network. The AHD market readiness and distribution management system has been utilized to introduce MedMira's Reveal(R) Rapid HIV-1 Antibody Test, the market's fastest FDA approved HIV test, and ThyroTec's ThyroTest(TM), the first ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening device. www.ahpartners.com
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E